Why the study?
Use of torsemide in heart failure is based on practical experience, and loop diuretic therapy poses clinical dilemmas due to a lack of robust evidence to guide treatment decisions.
Does torsemide optimize loop diuretic therapy compared to furosemide in heart failure patients?
Does torsemide optimize loop diuretic therapy compared to furosemide in heart failure patients?
This expert consensus provides practical recommendations and dosing algorithms for the use of torsemide in heart failure patients, highlighting its potential pharmacological and clinical advantages over furosemide.
Answers are grounded in this paper and cite their sources.
May support torsemide preference in HF; Level 5 evidence leaves open need for RCTs to guide practice.
Heart failure is associated with an increased frequency of hospitalization, reduced life span, and greater risk to public health, thus posing a challenge. In India, torsemide is one of the commonly used loop diuretics for decongestion in heart failure. However, this use of torsemide, including its dosing, and up/down titration, is based on practical experience. Loop diuretic therapy for heart failure patients poses several dilemmas due to the lack of robust evidence based on which treatment decisions can be made. To guide physicians on the optimal use of torsemide in heart failure patients with or without renal impairment, a panel of expert cardiologists and nephrologists from India convened to develop this expert opinion document for the use of torsemide. This expert opinion on torsemide will pave the way for optimal management with loop diuretic therapy in real-world heart failure patients.
No takes yet. Share an insight, caveat, or question.
Chopra et al. (2023) conducted a review in Heart failure. Torsemide vs. Furosemide was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: